<DOC>
	<DOCNO>NCT02345408</DOCNO>
	<brief_summary>This open-label phase 1-b study evaluate safety efficacy CCX872-B patient pancreatic adenocarcinoma also receive FOLFIRINOX chemotherapy .</brief_summary>
	<brief_title>Phase 1b Study CCX872-B Patients With Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm nonresectable pancreatic adenocarcinoma without metastasis Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤ 2 Anticipated life expectancy ≥ 12 week Radiographically measurable disease acc . RECIST 1.1 Use adequate contraception ( describe protocol ) Ability provide write informed consent comply study requirement Received cancer treatment investigational drug within 4 week prior screen Women pregnant breastfeeding Had major surgery within 4 week first dose study drug Inadequate liver , renal bone marrow function within 2 week first dose Serious concurrent illness , alter medical status uncontrolled medical condition Any infection require antibiotic antiviral treatment within 4 week screen Known active HIV , HBV HCV infection Inability swallow tablet History presence medical condition disease , opinion investigator , may place subject unacceptable risk study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>